Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials

Breast Cancer Research and Treatment

Volumn 152, Issue 2, 2015, Pages 377-387

  Loibl, Sibylle ^a,b   Jackisch, Christian ^b   Lederer, Bianca ^a   Untch, Michael ^c   Paepke, Stefan ^d   Kümmel, Sherko ^e   Schneeweiss, Andreas ^f   Huober, Jens ^g   Hilfrich, Jörn ^h   Hanusch, Claus ⁱ   Gerber, Bernd ^j   Eidtmann, Holger ^k   Denkert, Carsten ^l   Costa, Serban Dan ^m   Blohmer, Jens Uwe ^l   Nekljudova, Valentina ^a   Mehta, Keyur ^a   von Minckwitz, Gunter ^a  

^a German Breast Group ^*  (Germany)

^b SANA KLINIKUM OFFENBACH   (Germany)

^c Helios Klinikum   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e KLINIKEN ESSEN MITTE   (Germany)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^g UNIVERSITY HOSPITAL ULM   (Germany)

^h Eilenriedeklinik   (Germany)

ⁱ Klinikum Zum Roten Kreuz   (Germany)

^j ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^k UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^l CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^m UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

more..

Author keywords

Breast cancer; Chemotherapy; Neoadjuvant; Outcome; pCR; Survival; Young age

Indexed keywords

ANTHRACYCLINE DERIVATIVE; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER; EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; FEMALE; FOLLOW UP; HORMONE RECEPTOR NEGATIVE BREAST CANCER; HORMONE RECEPTOR POSITIVE BREAST CANCER; HUMAN; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PATHOLOGICAL COMPLETE REMISSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; YOUNG ADULT; AGED; BREAST NEOPLASMS; LYMPH NODE METASTASIS; META ANALYSIS; METABOLISM; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; ODDS RATIO; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SURVIVAL ANALYSIS; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84946492294     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3479-z     Document Type: Article

References (40)

1. Eisemann N, Waldmann A, Katalinic A (2013) Epidemiology of breast cancer, current figures and trends. Geburtsh Frauenheilk 73:130–135
2. DeSantis C, Siegel R, Bandi P, Jemal A (2011) Breast cancer statistics 2011. CA Cancer J Clin 61:409–418
3. Adami HO, Malker B, Holmberg L, Persson I, Stone B (1986) The relation between survival and age at diagnosis in breast cancer. N Engl J Med 315:559–563
4. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y et al (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26:3324–3330
5. Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H (2009) Breast cancer in young women: poor survival despite intensive treatment. PLoS One 4:e7695
6. Colleoni M, Rotmensz N, Robertson C, Orlando L, Viale G, Renne G et al (2002) Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 13:273–279
7. Maggard MA, O’Connell JB, Lane KE, Liu JH, Etzioni DA, Ko CY (2003) Do young breast cancer patients have worse outcomes? J Surg Res 113:109–113
8. Dubsky PC, Gnant MF, Taucher S, Roka S, Kandioler D, Pichler-Gebhard B et al (2002) Young age as an independent adverse prognostic factor in premenopausal patients with breast cancer. Clin Breast Cancer 3:65–72
9. Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM et al (2010) Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 124:133–140
10. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796–1804
11. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164–172
12. Cardoso F, Loibl S, Pagani O, Graziottin A, Panizza P, Martincich L et al (2012) The european society of breast cancer specialists recommendations for the management of young women with breast cancer. Eur J Cancer 48:3355–3377
13. Cardoso F, Harbeck N (2012) Breast cancer in young women–a clinical challenge to be addressed in a multidisciplinary setting. Breast Care 7:193–194
14. von Minckwitz G, Raab G, Caputo A, Schütte M, Hilfrich J, Blohmer JU et al (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23:2676–2685
15. von Minckwitz G, Blohmer JU, Raab G, Löhr A, Gerber B, Heinrich G et al (2005) In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 16:56–63
16. von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J et al (2008) Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 100:552–562
17. von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J et al (2008) Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 100:542–551
18. Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H et al (2010) Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from GeparQuattro study. J Clin Oncol 28:2024–2031
19. Untch M, Möbus V, Kuhn W, Muck BR, Thomssen C, Bauerfeind I et al (2009) Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol 27:2938–2945
20. Untch M, Fasching PA, Konecny GE, von Koch F, Conrad U, Fett W et al (2011) PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer–results at the time of surgery. Ann Oncol 22:1988–1998
21. Untch M, von Minckwitz G, Konecny GE, Conrad U, Fett W, Kurzeder C et al (2011) PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer–outcome on prognosis. Ann Oncol 22:1999–2006
22. Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R et al (2011) Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 29:3351–3357
23. von Minckwitz G, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S et al (2011) Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 125:145–156
24. von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H et al (2012) Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 366:299–309
25. Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU et al (2012) Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 13:135–144
26. von Minckwitz G, Costa SD, Raab G, Blohmer JU, Eidtmann H, Hilfrich J et al (2001) Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. J Clin Oncol 19:3506–3515
27. http://www.ago-online.de/fileadmin/downloads/leitlinien/mamma/march2012/14_2012E_Breast_Cancer_Specific_Situations.pdf Accessed 02 Feb 2015
28. http://www.ago-online.de/fileadmin/downloads/leitlinien/mamma/march2012/13_2012E_Adjuvant_Radiotherapy.pdf Accessed 02 Feb 2015
29. Bonetti M, Gelber RD (2004) Patterns of treatment effects in subsets of patients in clinical trials. Biostatistics 5:465–481
30. Arvold ND, Taghian AG, Niemierko A, Abi Raad RF, Sreedhara M, Nguyen PL et al (2011) Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol 29:3885–3891
31. Azim HA Jr, Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis M et al (2012) Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res 18:1341–1351
32. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379:432–444
33. Partridge AH, Gelber S, Piccart-Gebhart MJ, Focant F, Scullion M, Holmes E et al (2013) Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol 31:2692–2698
34. Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko SS et al (2007) Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea–a report from the Korean Breast Cancer Society. J Clin Oncol 25:2360–2368
35. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Godwin J, Gray R, Clarke M, Cutter D, Darby S et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771–784
36. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679–691
37. Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M et al (2015) Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372:436–446
38. Kroman N, Jensen MB, Wohlfahrt J, Mouridsen HT, Andersen PK, Melbye M (2000) Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ 320:474–478
39. Brouckaert O, Salihi R, Laenen A, Vanderhaegen J, Amant F, Leunen K et al (2012) Independent prognostic value of age depends on breast cancer subtype. Cancer Res 72(24):7–29
40. Liedtke C, Hess KR, Karn T, Rody A, Kiesel L, Hortobagyi GN et al (2013) The prognostic impact of age in patients with triple-negative breast cancer. Breast Cancer Res Treat 138:591–599